Metabolic Syndrome | ||||
---|---|---|---|---|
Variables | All Patients (n = 190) | Absent (n = 103) | Present (n = 87) | P value |
Age, yrs | 62.7 ± 9.2 | 62.6 ± 9.8 | 62.7 ± 8.4 | 0.964 |
Female gender | 20 (10.5%) | 7 (6.8%) | 13 (14.9%) | 0.068 |
BMI,kg/m2 | 24.9 ± 4.2 | 23.0 ± 3.2 | 27.1 ± 4.1 | P<0.0001 |
Expected operative risk (by EuroSCORE II) (%) | 3.5 ± 6.7 | 3.2 ± 6.9 | 4.0 ± 6.9 | 0.399 |
NYHA heart failure class (III/IV), n(%) | 66 (34.7%) | 27 (26.2%) | 39 (44.8%) | 0.007 |
Risk factors and concomitant diseases | ||||
Smoking | ||||
Never | 81 (42.6%) | 43 (41.7%) | 38 (43.7%) | 0.789 |
Former | 35 (18.4%) | 19 (18.4%) | 16 (18.4%) | 0.992 |
Current | 74 (38.9%) | 41 (38.9%) | 33 (37.9%) | 0.792 |
Obesity (BMI>25 kg/m2) | 18 (9.5%) | 4 (3.9%) | 14 (16.1%) | 0.004 |
Hypertension | 108 (56.8%) | 36 (35.0%) | 72 (82.8%) | P<0.0001 |
Diabetes mellitus | 63 (33.2%) | 19 (18.4%) | 44 (50.6%) | P<0.0001 |
Lipid profile | ||||
HDL cholesterol, mmol/L | 1.05 ± 0.69 | 1.14 ± 0.9 | 0.94 ± 0.24 | 0.038 |
LDL cholesterol, mmol/L | 2.97 ± 1.16 | 2.68 ± 1.06 | 3.30 ± 1.20 | P<0.001 |
Triglycerides, mmol/L | 1.6 ± 0.9 | 1.27 ± 0.43 | 2.0 ± 1.15 | P<0.0001 |
Fasting glycaemia, mmol/L | 6.5 ± 2.8 | 5.6 ± 1.9 | 7.6 ± 3.2 | P<0.0001 |
CK-MB, μg/L | 21.3 ± 33.9 | 18.6 ± 15.9 | 24.5 ± 47.1 | 0.231 |
Hyperuricemia | 50 (26.3%) | 22 (21.4%) | 28 (32.2%) | 0.091 |
COPD | 6 (3.2%) | 2 (1.9%) | 4 (4.6%) | 0.297 |
Peripheral vascular disease | 17 (8.9%) | 6 (5.8%) | 11 (12.6%) | 0.101 |
History of stroke | 15 (7.9%) | 6 (5.8%) | 9 (10.3%) | 0.250 |
Renal dysfunction (creatinine>150 μmol/L) | 12 (6.3%) | 4 (3.9%) | 8 (9.2%) | 0.134 |
Used of mechanical ventilation | 11 (5.8%) | 5 (4.9%) | 6 (6.9%) | 0.548 |
Details of coronary artery disease | ||||
Left main stenosis ≥50% | 57 (30%) | 31 (30.1%) | 26 (29.9%) | 0.975 |
2-vessel disease(≥75% stenosis) | 54 (28.4%) | 26 (25.2%) | 28 (32.2%) | 0.291 |
3-vessel disease(≥75% stenosis) | 119 (62.6%) | 63 (61.2%) | 56 (64.4%) | 0.649 |
Recent myocardial infarction (<30 days) | 69 (36.3%) | 38 (36.9%) | 31 (35.6%) | 0.857 |
Atrial fibrillation | 10 (5.3%) | 7(6.8%) | 3 (3.4%) | 0.303 |
Previous PCI | 24 (12.6%) | 17 (16.5%) | 7 (8.0%) | 0.080 |
Echocardiographic findings | ||||
LV ejection fraction (%) | 39.8 ± 6.4 | 39.3 ± 6.3 | 40.4 ± 6.6 | 0.237 |
LV diastolic dimension (mm) | 56.8 ± 6.9 | 56.5 ± 7.4 | 57.1 ± 6.2 | 0.505 |
Pulmonary hypertension | 59 (31.1%) | 35 (34.0%) | 24 (27.6%) | 0.343 |
Mitral valve insufficiency | 96 (50.5%) | 52 (50.5%) | 44 (50.6%) | 0.990 |
Left ventricular aneurysm | 31 (16.3%) | 20 (19.4%) | 11 (12.6%) | 0.208 |
Operative data | ||||
Urgent/emergency surgery | 7 (3.7%) | 3 (2.9%) | 4 (4.6%) | 0.705 |
On-pump bypass surgery | 54 (28.4%) | 31 (30.1%) | 23 (26.4%) | 0.577 |
IMA used as grafts | 161 (84.7%) | 85 (82.5%) | 76 (87.4%) | 0.356 |
Saphenous vein used as grafts | 180 (94.7%) | 96 (93.2%) | 84 (96.6%) | 0.303 |
Aneurysmectomy | 10 (5.3%) | 8 (7.9%) | 2 (2.3%) | 0.183 |
Mitral valve surgery | 17 (8.9%) | 10 (9.7%) | 7 (8.0%) | 0.689 |
No. of distal anastomosis | 2.6 ± 0.9 | 2.5 ± 0.93 | 2.75 ± 0.89 | 0.059 |